C57BL/6JCya-Gba1em1/Cya
Common Name
Gba1-KO
Product ID
S-KO-02190
Backgroud
C57BL/6JCya
Strain ID
KOCMP-14466-Gba1-B6J-VA
When using this mouse strain in a publication, please cite “Gba1-KO Mouse (Catalog S-KO-02190) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Basic Information
Strain Name
Gba1-KO
Strain ID
KOCMP-14466-Gba1-B6J-VA
Gene Name
Product ID
S-KO-02190
Gene Alias
GC, GCase, GLUC, Gba, betaGC
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 3
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000077367
NCBI RefSeq
NM_001077411
Target Region
Exon 9~11
Size of Effective Region
~0.9 kb
Overview of Gene Research
Gba1, which encodes the lysosomal enzyme glucocerebrosidase (GCase), is involved in sphingolipid metabolism [2]. GCase deficiency leads to abnormal accumulation of its substrates, and this gene is significantly associated with health conditions. Biallelic variants in Gba1 cause Gaucher disease, a lysosomal storage disorder, and carriers of Gba1 variants have an increased risk of developing Parkinson's disease (PD) [2].
In PD, Gba1-associated PD is recognized as a distinct entity within parkinsonian disorders [1]. Gba1 mutations contribute to PD development through mechanisms like 'haploinsufficiency' and 'gain of function' [1]. The 'gain of function' mechanism seems more plausible, where mutated GCase impacts cellular mechanisms for alpha-synuclein degradation, leading to its aggregation and neuronal cell damage [1]. In Gba1 E326K knock-in mice (a model for increased PD and dementia risk), Gba1 deficiency exacerbates neuroinflammation and promotes pathogenic alpha-synuclein transmission, intensifying disease pathology [3].
In summary, Gba1 is crucial for sphingolipid metabolism, and its dysfunction is closely linked to Gaucher disease and PD. Mouse models, such as the Gba1 E326K knock-in mice, have revealed the role of Gba1 in promoting neuroinflammation and alpha-synuclein-related pathogenesis in PD, enhancing our understanding of the disease mechanisms and potentially guiding new therapeutic strategies [3].
References:
1. Skrahin, Aliaksandr, Horowitz, Mia, Istaiti, Majdolen, Rolfs, Arndt, Zimran, Ari. 2024. GBA1-Associated Parkinson's Disease Is a Distinct Entity. In International journal of molecular sciences, 25, . doi:10.3390/ijms25137102. https://pubmed.ncbi.nlm.nih.gov/39000225/
2. Menozzi, Elisa, Toffoli, Marco, Schapira, Anthony H V. 2023. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. In Pharmacology & therapeutics, 246, 108419. doi:10.1016/j.pharmthera.2023.108419. https://pubmed.ncbi.nlm.nih.gov/37080432/
3. Kweon, Sin Ho, Ryu, Hye Guk, Kwon, Seung-Hwan, Kim, Sangjune, Ko, Han Seok. . Gba1 E326K renders motor and non-motor symptoms with pathological α-synuclein, tau and glial activation. In Brain : a journal of neurology, 147, 4072-4083. doi:10.1093/brain/awae222. https://pubmed.ncbi.nlm.nih.gov/38976650/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.